Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA.
J Neurosurg. 2010 Oct;113(4):908-12. doi: 10.3171/2009.12.JNS09707.
Many patients undergoing carotid endarterectomy (CEA) regularly take clopidogrel, a permanent platelet inhibitor. The authors sought to determine whether taking clopidogrel in the period before CEA leads to more bleeding or other complications.
The authors performed a retrospective, institutional review board–approved review of 182 consecutive patients who underwent CEA. Clinical, radiographic, and surgical data were gleaned from hospital and clinic records. Analysis was based on the presence or absence of clopidogrel in patients undergoing CEA and was performed twice by considering clopidogrel use within 8 days and within 5 days of surgery to define the groups.
Taking clopidogrel within 8 days before surgery resulted in no statistical increase in any measure of morbidity or death. Taking clopidogrel within 5 days was associated with a small but significant increase in operative blood loss and conservatively managed postoperative neck swelling. No measure of permanent morbidity or death was increased in either clopidogrel group.
Findings in this study support the safety of preoperative clopidogrel in patients undergoing CEA.
许多接受颈动脉内膜切除术(CEA)的患者经常服用氯吡格雷,这是一种永久性血小板抑制剂。作者旨在确定在 CEA 前服用氯吡格雷是否会导致更多出血或其他并发症。
作者对 182 例连续接受 CEA 的患者进行了回顾性、机构审查委员会批准的回顾性研究。从医院和诊所记录中收集临床、影像学和手术数据。分析基于 CEA 患者是否服用氯吡格雷,并通过考虑氯吡格雷在手术前 8 天和 5 天内的使用进行了两次,以定义两组。
手术前 8 天内服用氯吡格雷并没有导致任何发病率或死亡率的统计学增加。手术前 5 天内服用氯吡格雷与手术失血增加和保守治疗的术后颈部肿胀略有显著相关。在氯吡格雷组中,任何永久性发病率或死亡率的指标均未增加。
本研究的结果支持 CEA 患者术前使用氯吡格雷的安全性。